Literature DB >> 26535869

Fecal Calprotectin Measured By Patients at Home Using Smartphones--A New Clinical Tool in Monitoring Patients with Inflammatory Bowel Disease.

Kristoffer Kofod Vinding1, Henriette Elsberg, Tine Thorkilgaard, Erika Belard, Natalia Pedersen, Margarita Elkjaer, Dorte Marker, Katrine Carlsen, Johan Burisch, Pia Munkholm.   

Abstract

BACKGROUND: Fecal calprotectin is a reliable noninvasive marker for intestinal inflammation usable for monitoring patients with inflammatory bowel disease. Tests are usually performed by enzyme-linked immunosorbent assay (ELISA), which is time consuming and delays results, thus limiting its use in clinical practice. Our aim was to evaluate CalproSmart, a new rapid test for fecal calprotectin performed by patients themselves at home, and compare it to gold standard ELISA.
METHODS: A total of 221 patients with inflammatory bowel disease (115 ulcerative colitis and 106 Crohn's disease) were included. The CalproSmart test involves extraction of feces, application to the lateral flow device, and taking a picture with a smartphone after 10 minutes of incubation. Results appear on the screen within seconds. Patients were instructed at inclusion and had a video guide of the procedure as support. When using CalproSmart at home, patients also sent in 2 fecal samples to be analyzed by ELISA.
RESULTS: Totally, 894 fecal calprotectin results were obtained by ELISA, and 632 of them from CalproSmart. The correlation coefficient was 0.685, higher for academics than nonacademics (0.768 versus 0.637; P = 0.0037). The intra-assay and interassay coefficients of variation of the CalproSmart test were 4.42% and 12.49%, respectively. The sensitivity, specificity, positive predictive value, and negative predictive value were 82%, 85%, 47%, and 97%, respectively, with an optimal cutoff at 150 μg/g.
CONCLUSIONS: The CalproSmart test performed by patients with inflammatory bowel disease for fast assessment of gut inflammation seems a reliable alternative to ELISA and presents a new way of monitoring patients by eHealth.

Entities:  

Mesh:

Substances:

Year:  2016        PMID: 26535869     DOI: 10.1097/MIB.0000000000000619

Source DB:  PubMed          Journal:  Inflamm Bowel Dis        ISSN: 1078-0998            Impact factor:   5.325


  14 in total

1.  Validation of a care pathway for the use of faecal calprotectin in monitoring patients with Crohn's disease.

Authors:  James Turvill; Lisa Rook; Maxine Rawle; Gerry Robins; Simon Smale; Prashant Kant; Anne Phillips
Journal:  Frontline Gastroenterol       Date:  2017-01-30

2.  Optimal Range of Fecal Calprotectin for Predicting Mucosal Healing in Patients with Inflammatory Bowel Disease: A Systematic Review and Meta-Analysis.

Authors:  Bing-Jie Xiang; Min Jiang; Ming-Jun Sun; Cong Dai
Journal:  Visc Med       Date:  2021-01-21

3.  International consensus on methodological issues in standardization of fecal calprotectin measurement in inflammatory bowel diseases.

Authors:  Ferdinando D'Amico; David T Rubin; Paulo Gustavo Kotze; Fernando Magro; Britta Siegmund; Taku Kobayashi; Pablo A Olivera; Peter Bossuyt; Lieven Pouillon; Edouard Louis; Eugeni Domènech; Subrata Ghosh; Silvio Danese; Laurent Peyrin-Biroulet
Journal:  United European Gastroenterol J       Date:  2021-05-07       Impact factor: 4.623

Review 4.  Damage-associated molecular patterns in inflammatory bowel disease: From biomarkers to therapeutic targets.

Authors:  Hayandra Ferreira Nanini; Claudio Bernardazzi; Fernando Castro; Heitor Siffert Pereira de Souza
Journal:  World J Gastroenterol       Date:  2018-11-07       Impact factor: 5.742

5.  Head-to-head comparison of three stool calprotectin tests for home use.

Authors:  Sjoukje-Marije Haisma; Anne Galaurchi; Shatha Almahwzi; Joy A Adekanmi Balogun; Anneke C Muller Kobold; Patrick F van Rheenen
Journal:  PLoS One       Date:  2019-04-18       Impact factor: 3.240

6.  Disease monitoring of biologic treatment in IBD: early impact and future implications of COVID-19 pandemic.

Authors:  Stephanie Shields; Allan Dunlop; John Paul Seenan; Jonathan Macdonald
Journal:  Frontline Gastroenterol       Date:  2020-09-30

7.  Monitoring-Based Model for Personalizing the Clinical Process of Crohn's Disease.

Authors:  Alberto de Ramón-Fernández; Daniel Ruiz-Fernández; Diego Marcos-Jorquera; Virgilio Gilart-Iglesias; Víctor Vives-Boix
Journal:  Sensors (Basel)       Date:  2017-07-05       Impact factor: 3.576

Review 8.  Quality of care in inflammatory bowel diseases: What is the best way to better outcomes?

Authors:  Matthew Strohl; Lorant Gonczi; Zsuzsanna Kurt; Talat Bessissow; Peter L Lakatos
Journal:  World J Gastroenterol       Date:  2018-06-14       Impact factor: 5.742

9.  Experience of patients with inflammatory bowel disease in using a home fecal calprotectin test as an objective reported outcome for self-monitoring.

Authors:  Shu-Chen Wei; Chien-Chih Tung; Meng-Tzu Weng; Jau-Min Wong
Journal:  Intest Res       Date:  2018-10-10

10.  Home-based fecal calprotectin test is expected to play an important role in patients with inflammatory bowel diseases.

Authors:  Young-Ho Kim
Journal:  Intest Res       Date:  2018-10-25
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.